SummaryThrombotic thrombocytopenic purpura (TTP) is an acute, rare, lifethreatening disorder. This report presents the South East (SE) England registry for TTP, from April 2002 to December 2006, which included 176 patients and 236 acute episodes; 75% of patients were female and 25% were male, overall median age at presentation was 42 years. Mortality was 8AE5%, most cases died before treatment was instigated. The main ethnic groups were Caucasian (64%) and Afro Caribbean (27%). Seventy-seven percent of cases were idiopathic, 5% were congenital and the remaining cases had a defined precipitant. Neurological features were the most prevalent, but cardiac involvement accounted for 42% of presenting features. The overall median number of plasma exchanges (PEXs) to remission was 15; between April 2002 and December 2003, the median number of PEXs was 19 and it was 12 between January 2004 and December 2006 (P < 0AE0001). In the latter period, adjuvant therapies were reduced, but Rituximab was increased. ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity was <10% in 74% and 95% of these cases had positive IgG antibodies to ADAMTS 13. Renal impairment and delayed normalisation of platelet count were the main differences between idiopathic and secondary TTP.
IntroductionMultiple myeloma (MM) is an incurable plasma cell (PC) malignancy of the bone marrow (BM). Although acquired genetic events and the tumor microenvironment are well-established regulators of myeloma cell survival and proliferation pathways, the identity and functional properties of the myeloma-propagating cells have been a matter of controversy. 1,2 The terminal differentiation of normal mature B lymphocytes to immunoglobulin (Ig)-secreting PCs entails conversion of antigennaive to antigen-experienced B cells in the germinal center of secondary lymphoid organs and their subsequent differentiation to either memory B cells or PCs. 3,4 Each stage of B-cell differentiation can be defined by surface markers with naive and memory B cells expressing CD19 and terminally differentiated normal and malignant PCs, but not B cells, expressing CD138 (Syndecan-1). 5,6 Given this linear B-cell lineage developmental process, it was suggested that myeloma cell growth is sustained by a minority of cells more immature than the PC. This hypothesis is supported by the presence of CD19 ϩ CD138 Ϫ clonotypic B cells (ie, cells sharing the same Ig heavy chain [IgH] complementarity region 3 [CDR3] sequence with the myeloma PCs) in peripheral blood (PB) and BM of patients with MM. 7-10 Indeed, because CD138 Ϫ but not CD138 ϩ PCs were found to lead to myeloma engraftment in NOD/SCID mice, it was proposed that CD138 Ϫ cells were the principal myeloma-propagating or "myeloma stem" cells [11][12][13][14] Earlier studies, For personal use only. on May 9, 2018. by guest www.bloodjournal.org From though, using a huSCID mouse model, had concluded that mature PCs (defined as CD38 hi CD45 Ϫ ), and not the CD19 ϩ B-cell fraction, contained the entire myeloma-propagating activity, 15 whereas more recently, CD19 Ϫ CD138 Ϫ as well as CD138 ϩ cells engrafted SCID-rab mice with myeloma. 16 Furthermore, whereas earlier studies reported that the myeloma side population is enriched in clonogenic activity and identifies with CD138 Ϫ but not CD138 ϩ myeloma cells, 13 recent evidence shows that both CD138 ϩ and CD138 Ϫ cells are included in the highly clonogenic myeloma side population. 17 Whether these discrepancies result from different animal models and phenotypic definitions of PC is not clear. Here, through a detailed phenotypic and genetic analysis of primary human myeloma cells and a prospective, dynamic ex vivo and in vivo study of the constituents of the myeloma cellular architecture, we show that a phenotypic and functional interconvertible state between CD138 ϩ and CD138 Ϫ cells underpins myelomapropagating activity and clinical drug resistance. Methods Patient and normal donor BM and PB samplesPatient BM and PB samples were obtained after written informed consent and appropriate institutional ethics committee approval. Patient characteristics are shown in supplemental Table 1 (available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Diagnosis, remission, and relapse of MM were defined accordi...
Summary. Venous thromboembolism (VTE) is not a feature of thrombotic thrombocytopenic purpura (TTP), but there has been a recent report of VTE in association with plasma exchange (PEX) treatment for TTP using the solvent detergent (SD) plasma, PLAS+ Ò SD. We reviewed the occurrence of VTE in 68 consecutive patients with TTP (25 men, 43 women). Eight documented VTE events [six deep venous thromboses (DVTs), three pulmonary emboli] were identified in seven patients (all female) during PEX therapy. All six DVTs were associated with central lines at the site of thrombosis. Other known precipitating factors included pregnancy, immobility, obesity and factor V Leiden heterozygosity. VTE occurred at a mean of 53 d following the first PEX. The European SD plasma, Octaplas Ò was the last plasma to be used in PEX prior to the VTE in 7/8 events. This is the first report of VTE following Octaplas Ò infusion. VTE is a multifactorial disease and, although several known precipitating factors were present in all patients in this study, the use of large volumes of SD plasma in PEX may be an additional risk factor. We recommend prevention of VTE with graduated elastic compression stockings (class I) at diagnosis and prophylactic low-molecular-weight heparin once the platelet count rises above 50 · 10 9 /l.
Replacement of normal levels of von Willebrand factor-cleaving protease (VWF:CP, ADAMTS13) activity from infused plasma is important in plasma exchange (PEX) for the treatment of thrombotic thrombocytopenic purpura (TTP) patients. We have studied the VWF:CP activity, VWF multimer distribution, VWF:Ag, protein S (PS) activity and free PS antigen levels in fresh frozen plasma (FFP), cryosupernatant (CSP) and virally inactivated components treated with methylene blue/light (MB) or solvent detergent (SD) processes. VWF:CP activity was normal in all components tested and was retained following overnight storage at room temperature. CSP and SD plasma contained reduced levels of the highest molecular weight VWF multimers. Protein S activity was reduced below the normal range in SD plasma, but within the normal range for the other components tested. Virally inactivated SD- and MB-treated plasma may be an effective alternative to FFP and CSP in PEX for TTP. Reduced PS activity in SD plasma may predispose to venous thromboembolism, especially if infused in large volumes.
S-59-treated CSP retained adequate levels of critical plasma proteins for plasma exchange therapy in acute TTP. The data indicate good preservation of hemostasis control proteins such as PS, alpha(2)-antiplasmin, and VWF:CP activity (ADAMTS13).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.